Strider Report Flags 800-Plus PRC Biotech Firms as BIOSECURE Act Targets

A private strategic intelligence firm released findings this week that deserve close scrutiny before they get treated as settled fact, and also shouldn't be ignored.

<cite index="20-2">Strider Technologies published a report on October 8 identifying more than 800 People's Republic of China-based biotechnology companies with ties to the country's military, intelligence, and internal security-affiliated institutions.</cite> The report's framing is explicitly tied to implementation of a specific law: <cite index="20-3,20-4">the BIOSECURE Act, signed into law in December 2025 as part of the FY2026 National Defense Authorization Act, restricts U.S. federal procurement from, and funding to, "biotechnology companies of concern," and automatically covers firms on the Pentagon's Section 1260H list while directing the Office of Management and Budget to publish and maintain an expanded list of qualifying entities.</cite>

Strider is positioning its findings as raw material for that expanded list. <cite index="20-6">The report, titled "Implementing the BIOSECURE Act: Hundreds of PRC Biotech Firms Linked to State Security Entities Pose Risks to Sensitive Genomic Data and National Security", argues that portions of the PRC biotechnology sector are embedded within formal military procurement and research networks.</cite>

The specific numbers in the report break down as follows: <cite index="20-8">more than 350 PRC biotechnology companies are registered as suppliers to the People's Liberation Army, plus more than 200 others that are subsidiaries of those suppliers.</cite> <cite index="21-3">An additional category covers more than 350 PRC biotechnology companies that have co-authored academic research with PRC military, intelligence, or internal security-affiliated organizations since 2020.</cite>

The methodology here matters and warrants caution. Strider is a vendor with a commercial interest in the national security screening market. The report is a press release artifact, not a peer-reviewed analysis or a government assessment. Co-authoring a paper with a military-affiliated university, a common structural feature of Chinese academia, is not the same as active weapons-program involvement. Strider does not appear to claim otherwise, but that distinction will get lost in downstream use of the headline number.

The case studies the report highlights are more specific. <cite index="25-4">BGI Group, a leading PRC-based genomics company, has received tens of millions of dollars in subsidies from the PRC government and operates the China National GeneBank Database, the country's first national-level gene repository and a centralized platform for biological big data sharing and application.</cite> <cite index="25-5">ANNGEEN Technologies, a Beijing gene sequencing firm, has collaborated on patent research with the Ministry of Public Security's Institute of Forensic Science to improve DNA testing methods used for forensic identification.</cite> Those are concrete affiliations, not inferred ones.

The law's implementation track record adds context. <cite index="22-3">The Department of Defense added WuXi AppTec to its list of "Chinese military companies" operating in the United States on June 8, 2026.</cite> <cite index="22-5">WuXi AppTec has already filed a legal challenge to that designation, and other companies may follow suit.</cite> The legal contest shows that even the narrower, government-generated list faces due-process questions that the BIOSECURE Act's drafters will have to defend in court.

The NSCEB, the National Security Commission on Emerging Biotechnology, flagged the broader structural issue in its October 2026 newsletter. <cite index="13-3,13-4">A bill introduced September 24 in both chambers, the Protecting Biological Data as Critical Infrastructure Act, would direct CISA to designate systems handling genomic sequences and sensitive biometric data as critical infrastructure and mandate collaboration between CISA and biotechnology stakeholders to create security protocols across sectors.</cite>

<cite index="19-6">Strider urges policymakers and business leaders to evaluate supply chains, investment flows, and research partnerships to mitigate potential foreign intelligence and data exposure.</cite> <cite index="21-8">The report also urges policymakers to close the gap the law leaves around U.S. and allied companies with equivalent military and intelligence affiliations</cite>, an acknowledgment that the framing of this as a China-specific problem has limits.

The practical compliance burden falls on U.S. biotech and pharma companies that hold federal contracts. <cite index="23-6">U.S. biotechnology companies with related federal contracts, grants, or loans will be required to purge their supply chains of equipment from PRC biotechnology firms to stay compliant with the BIOSECURE Act.</cite> Eight hundred firms is a number that, if the OMB list approaches it, will create significant supply chain disruption well before the national security benefit is measurable. That's not an argument against the law. It's a planning problem that agencies and contractors haven't fully priced in.

Sources cited:
- Strider Technologies press release (PR Newswire) (https://www.prnewswire.com/news-releases/strider-report-identifies-more-than-800-chinese-biotech-firms-linked-to-prc-military-and-security-services-302901429.html)
- Strider Technologies newsroom (https://striderintel.com/newsroom/strider-report-identifies-more-than-800-chinese-biotech-firms-linked-to-prc-military-and-security-services/)
- OODAloop report summary (https://oodaloop.com/briefs/technology/strider-report-identifies-over-800-chinese-biotech-firms-linked-to-prc-military-and-security-services/)
- Arnold Porter: BIOSECURE Act, Section 1260H, and COINS Act Developments (https://www.arnoldporter.com/en/perspectives/advisories/2026/06/national-security-controls-and-the-life-sciences-sector)
- Mayer Brown: Biotechnology and National Security (https://www.mayerbrown.com/en/insights/publications/2026/08/biotechnology-and-national-security-washingtons-expanding-scrutiny-of-the-life-sciences)
- NSCEB Monthly Newsletter, October 2026 (https://www.biotech.senate.gov/press-releases/nsceb-monthly-newsletter-october-2026/)